Significant Agreements - Additional Information (Detail) - USD ($) $ in Thousands							1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 23, 2024	May 29, 2024	Apr. 23, 2024	Mar. 04, 2024	May 26, 2021	Dec. 16, 2019	Mar. 31, 2025	Jul. 31, 2024	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unamortized finite-lived intangible asset									$ 19,610		$ 19,610		$ 15,630
Current portion of deferred revenue									1,847		1,847		1,554
Deferred revenue, noncurrent									3,371		3,371		3,233
Deferred revenue											431	$ 0
Takeda Asset Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront of cash payment						$ 1,000
Takeda Asset Agreement [Member] | Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs, shares					6,470,382
Takeda Asset Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share Issuance						9,857,143
Common stock issued, share issuance costs						$ 9,900
Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs, shares					9,857,143
Merck License Agreement [Member] | Research And Development Expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment											8,000
Viracta License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of Milestones			$ 9,000
Viracta License Agreement [Member] | Other Intangible Assets [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of Milestones											9,000
Viracta License Agreement [Member] | PRV
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unamortized finite-lived intangible asset									6,900		6,900
Proceeds from sale of priority review voucher		$ 108,000											$ 108,000
Payment to obligation of license agreement		$ 8,100
Viracta License Agreement [Member] | Research And Development Expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment				$ 5,000
Payment of Milestones											36,000
Upfront of cash payment											2,000
Sprint Bioscience Agreement [Member] | Research And Development Expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment											3,000
MabCare License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment								$ 55,000
MabCare License Agreement [Member] | Research And Development Expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of Milestones											20,000
Milestone payments not yet paid											1,132,000
License agreement with Ipsen Pharma SAS [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments not yet received											380,000
Proceeds from issuance of private placement	$ 40,000
Transaction Price	78,200
Equity Investment	7,400
License revenue									300	$ 0	600	$ 0
License agreement with Ipsen Pharma SAS [Member] | Current Member
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Current portion of deferred revenue									1,800		1,800
License agreement with Ipsen Pharma SAS [Member] | Noncurrent Member
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue, noncurrent									$ 3,400		$ 3,400
License agreement with Ipsen Pharma SAS [Member] | License revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment	$ 70,800
License agreement with Ipsen Pharma SAS [Member] | Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share Issuance	2,341,495
Volume weighted average price	17.00%
License agreement with Ipsen Pharma SAS [Member] | Research And Development Expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of Milestones							$ 4,000